MAP4343 

MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents^[1][2].

MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro^[1].
MAP4343 (30 μM; 2-8 d) stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells^[1].
MAP4343 (20 μM; 1 h) protects against microtubule depolymerization induced by Nocodazole in PC12 cells^[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MAP4343 (12 mg/kg; daily s.c. for 28 d) improves the recovery of locomotor function after spinal cord injury (SCI) in rats^[2].
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases MAP2 levels in spinal cord after SCI in rats^[2].
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases the size of lumbar spinal motoneurons' dendrite arbours after SCI in rats^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

330.50

C₂₂H₃₄O₂

511-26-2

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

• [1]. Fontaine-Lenoir V, et, al. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4711-6.  [Content Brief]

  [2]. Duchossoy Y, et, al. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66.  [Content Brief]